Skin care composition for improving skin redness and dryness problems and application
Through the composition of hyaluronic acid lysine copper chelate, powdered hexamonase extract and polysin extract, the problem of existing skin care products being difficult to improve sensitive skin redness and dryness, achieving effective soothing and moisturizing effects , significantly improves the health of the skin.
Patent Information
- Application Number
- CN202411106308.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-13
AI Technical Summary
Existing skin care products are difficult to effectively improve the deep repair of sensitive skin, and the ingredients are complex, costly, and have no significant effects, which cannot relieve skin redness and dryness in the long run.
Compositions of hyaluronic acid lysine copper chelate, hyaluronic acid lysine extract and polysin extract are used to promote the expression of moisturizing factors HAS1 and AQP3, and to inhibit the expression of inflammation-related factors PGE2 and TNF-α, providing soothing and relieving Moisturizing effect.
The composition significantly improves skin redness and dryness problems, has good stability and safety, can be used for a long time, reduces the irritation of the product, and significantly improves the skin's moisturizing ability.
Smart Images

Figure BDA0004990919900000041 
Figure BDA0004990919900000051 
Figure BDA0004990919900000061
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cosmetics, and in particular to a skin care composition for improving skin redness and dryness and its application. Background Art
[0002] In recent years, the incidence of sensitive skin (SS) has gradually increased, seriously affecting people's quality of life and becoming a global health issue of great concern. Based on the International Forum on Itch Research (IFSI) and the "Chinese Expert Consensus on the Diagnosis and Treatment of Sensitive Skin" (2017 edition), sensitive skin is defined as a syndrome in which the skin is subjected to minor external stimuli and experiences paroxysmal or periodic burning, paroxysmal redness, tingling, itching and tightness, with or without persistent erythema. Sensitive skin is most likely to occur on the face. Current studies believe that the occurrence of sensitive skin is a complex process involving the skin barrier-neurovascular response-innate immune inflammation. The main cause is impaired skin barrier function, increased transepidermal water loss, reduced stratum corneum water content, decreased moisturizing and water-locking ability, causing dry skin, and enhancing the penetration of irritants or allergens. At the same time, in terms of immune inflammatory response, the irritant stimulates immune cells to release proinflammatory inflammatory factors or inflammatory mediators, such as PEG-2, TNF-α, etc., causing symptoms such as skin redness, itching, burning and tingling. Therefore, the care of sensitive skin must repair the damaged skin barrier while reducing the release of inflammatory cytokines in the skin.
[0003] The formation and development mechanism of sensitive skin is complex, which makes it extremely difficult to repair and improve sensitive skin. Many products on the market can only temporarily relieve skin sensitivity, but do not have a deep repair effect on sensitive skin. In addition, most of the existing soothing and repairing compositions are formulated by superimposing a large number of repairing and soothing ingredients. The ingredients are complex, the mechanism of action is unclear, the cost is high, and the effect is not significant. Therefore, it is necessary to develop products with simple ingredients, mild and non-irritating, good soothing effect, and improvement of skin redness and dryness. Summary of the invention
[0004] In view of the above problems, the present invention provides a skin care composition and application for improving skin redness and dryness. The composition of the present invention is compounded with hyaluronic acid lysine copper chelate, Stephania tetrandra extract and Polygonatum sibiricum extract. It has been verified by experiments that it has good soothing and moisturizing effects, can be used in cosmetics to improve skin redness, dryness and other problems, and has good application prospects in cosmetics.
[0005] In order to achieve the above technical objectives, the technical solution adopted by the present invention is as follows: a skin care composition for improving skin redness and dryness problems, characterized in that its active ingredients are hyaluronic acid lysine copper chelate, Stephania tetrandra extract and Polygonatum sibiricum extract, and the mass fractions of each active ingredient are: 0.1-1.0 parts of hyaluronic acid lysine copper chelate, 1.0-15.0 parts of Stephania tetrandra extract, and 1.0-15.0 parts of Polygonatum sibiricum extract.
[0006] The composition also includes solvents butylene glycol and water.
[0007] Preferably, the components and weight proportions thereof are: 0.5-1.0 parts of hyaluronic acid lysine copper chelate, 5.0-10.0 parts of Stephania tetrandra extract, 5.0-10.0 parts of Polygonatum sibiricum extract, 12.0-18.0 parts of butylene glycol, and 100 parts of water.
[0008] Preparation method: Mix the polygonatum sibiricum extract, the stephania tetrandra extract and butylene glycol together, then add hyaluronic acid lysine copper chelate and dissolve in purified water to make up to 100 parts.
[0009] The hyaluronic acid lysine copper chelate used in the present invention can be commercially available or obtained by a salt formation method (application number: CN202410478415.3). The hyaluronic acid lysine copper chelate used in the embodiment of the present invention is obtained by Example 1 of CN202410478415.3.
[0010] The method for obtaining the powder stephenci extract is commercially available or obtained by the following method: an appropriate amount of dried powder stephenci powder is extracted by ultrasound-assisted low eutectic solvent extraction, the extract is filtered, and the filtrate is concentrated and then butanediol is added to obtain the powder stephenci extract. The concentration is 0.3-0.8 g / mL based on the crude drug, that is, 0.3-0.8 g of dried powder stephenci powder is used to obtain 1 mL of powder stephenci extract (solution).
[0011] Furthermore, the specific steps are as follows:
[0012] (1) A low eutectic solvent is prepared by an oil bath heating and stirring method, wherein the hydrogen bond acceptor betaine and the hydrogen bond donor 1,2-propylene glycol are heated and stirred at 75 to 85° C. for 2 to 6 hours in a molar ratio of 1:2 until a clear and uniform solution is formed, and then the solution is placed in a vacuum drying oven at a temperature higher than the melting point to dry, and 2 to 5 times the mass of water is added to the solution to reduce the viscosity;
[0013] (2) taking an appropriate amount of Stephania tetrandra powder and placing it in the low eutectic solvent prepared in step (1), with a solid-liquid ratio of 1:10 to 1:15, and ultrasonically extracting at an ultrasonic power of 200 to 300 W for 30 to 60 minutes at room temperature, filtering after the extraction is completed, and repeatedly extracting the residue once, with a solid-liquid ratio of 1:8 to 1:10 for the second extraction, and an extraction time of 20 to 40 minutes, and combining the two filtrates and filtering;
[0014] (3) The filtrate obtained in step (2) is concentrated under reduced pressure at 65° C. to 85° C., butanediol in an amount equal to the mass of the concentrate is added, the mixture is stirred and mixed evenly, and the extract of Stephania tetrandra is obtained after filtering.
[0015] The method for obtaining the polygonatum extract is commercially available or obtained by the following method: an appropriate amount of dried polygonatum powder is extracted by supercritical fluid extraction, the extract is filtered, and glycerol is added after the filtrate is concentrated. The concentration is 0.4-1.0 g / mL based on the crude drug, that is, 0.4-1.0 g of dried polygonatum powder is used to obtain 1 mL of polygonatum extract (solution).
[0016] Furthermore, the specific steps are as follows:
[0017] (1) Take an appropriate amount of dried polygonatum powder and place it in an extractor, set the temperature to 50-60°C, the pressure to 20-40 MPa, the flow rate of 60%-80% ethanol entrainer to 0.3-0.5 mL / min, and the flow rate of CO2 to 1.5-3.0 mL / min, and extract and collect for 2-4 hours after the parameters are stable, and collect the filtrate and filter it;
[0018] (2) The filtrate obtained in step (1) is concentrated under reduced pressure at 55° C. to 70° C., glycerin in an amount of 1 to 2 times the mass of the concentrated solution is added, the mixture is stirred and mixed uniformly, and the polygonatum sibiricum extract is obtained after filtering.
[0019] Hyaluronic acid lysine copper chelate has high moisturizing properties and better skin adhesion, has a significant inhibitory effect on 5α-reductase, can effectively control oil, prevent and treat common acne, improve skin water and oil balance, prevent seborrheic alopecia and improve hair quality, repair skin and mucous membrane damage, promote the production of elastin and collagen, prevent and reduce skin wrinkles, make the skin smooth and elastic, play an anti-wrinkle and firming effect, and improve facial aging.
[0020] Stephania tetrandra is a natural ingredient with multiple skin care benefits, mainly including anti-inflammatory, anti-allergic, anti-aging properties. It is derived from the dried root of the plant Stephania tetrandra of the Menispermaceae family and has a wide range of medical and cosmetic applications.
[0021] Polygonatum sibiricum is a commonly used Chinese medicinal material, rich in various active ingredients such as polygonatum glycoside and baicalein, which can improve skin problems through anti-oxidation, heat-clearing and detoxification.
[0022] The second aspect of the present invention provides the use of the above composition in the preparation of skin care cosmetics for improving skin redness and dryness. The present invention has verified through experiments that the above composition can promote the expression of moisturizing-related factors HAS1 (hyaluronic acid synthase 1 gene) and AQP3, inhibit the expression of inflammation-related factors PGE2 and TNF-α, achieve soothing and moisturizing effects, and is safe and has no toxic side effects. Therefore, it can be used in skin care cosmetics for improving skin redness and dryness.
[0023] The third aspect of the present invention provides a skin care cosmetic for improving skin redness and dryness, wherein the cosmetic comprises the above-mentioned skin care composition for improving skin redness and dryness.
[0024] Furthermore, based on the total weight of the skin care cosmetic for improving skin redness and dryness, the amount of the composition added is 1.0-10.0%. More preferably, the amount of the composition added is 3.0-8.0%.
[0025] Furthermore, the skin care cosmetics for improving skin redness and dryness problems also include: one or a combination of two or more of an emulsifier, a moisturizer, a humectant, a rheology modifier, and a preservative.
[0026] At the same time, the present invention can also prepare different cosmetic dosage forms, such as essence water, essence liquid, facial mask, essence milk, essence cream, etc. by reasonably adding the above-mentioned raw material ingredients. At the same time, based on the above-mentioned basic cosmetic categories, further derived cosmetic categories are prepared, which obviously belong to the protection scope of this application.
[0027] Beneficial effects of the present invention:
[0028] (1) The present invention combines hyaluronic acid lysine copper chelate, Stephania tetrandra extract and Polygonatum sibiricum extract, and the three synergistically enhance the effect, which can improve the redness and dryness of the skin by promoting the expression of moisturizing-related factors HAS1 (hyaluronic acid synthase 1 gene) and AQP3, inhibiting the expression of inflammation-related factors PGE2 and TNF-α, and achieving the effect of improving the redness and dryness of the skin in vitro.
[0029] (2) The composition of the present invention is used in acid-brushing mud mask. Stability experiments have shown that, under low pH conditions, the composition can maintain the stability of the mud mask product and its appearance is uniform. It has also been found that the composition can greatly reduce the irritation of the acid-brushing mud mask. DETAILED DESCRIPTION
[0030] The present invention is further described below by examples, but the present invention is not limited to the scope of the embodiments. Based on the embodiments in the present invention, any changes to the present invention by those skilled in the art without creative work are all within the scope of the present invention. Meanwhile, in the embodiments of the present invention, unless otherwise specified, all preparation raw materials are commercially available products well known to those skilled in the art.
[0031] Examples 1 to 4 and Comparative Examples 1 to 6:
[0032] The raw material proportions of Examples 1 to 4 and Comparative Examples 1 to 6 are shown in Table 1 below, calculated in parts by mass. The preparation method is as follows: Mix the polygonatum sibiricum extract, the stephenciia tetrandra extract and butanediol together, then add hyaluronic acid lysine copper chelate and dissolve in purified water to make up to 100 parts.
[0033] Table 1 Specific examples and comparative examples ingredient list
[0034]
[0035] The hyaluronic acid lysine copper chelate used in the embodiment of the present invention is obtained by Example 1 of CN202410478415.3. Specifically, after sodium hyaluronate and hydrochloride lysine copper chelate are mixed and dissolved evenly, catalysts EDCI and NHS are added, and after the reaction is kept warm, an appropriate amount of ethanol is added for precipitation and purification, filtration, dehydration with anhydrous ethanol and drying under reduced pressure to obtain a blue granular powder, sample 1-6.
[0036] The powdered tetrandra extract is obtained by the following method:
[0037] (1) preparing a low eutectic solvent: betaine and 1,2-propylene glycol were mixed in a molar ratio of 1:2, heated and stirred at 80° C. for 4.5 h until a clear and uniform solution was formed, and then the solution was placed in a vacuum drying oven at a temperature higher than the melting point for 24 h. To reduce the viscosity, 3 times the mass of water was added to the solution;
[0038] (2) taking an appropriate amount of Stephania tetrandra powder and placing it in the low eutectic solvent prepared in step (1), with a solid-liquid ratio of 1:12, and ultrasonically extracting at room temperature at an ultrasonic power of 250 W for 45 minutes. After the extraction is completed, filtering is performed, and the residue is repeatedly extracted once. The solid-liquid ratio of the second extraction is 1:8, and the extraction time is 30 minutes. The two filtrates are combined and filtered;
[0039] (3) The filtrate obtained in step (2) is concentrated under reduced pressure at 65°C to 85°C, butanediol of the same mass as the concentrate is added, the mixture is stirred and mixed evenly, and the extract of Stephania tetrandra is obtained after filtration. The concentration of Stephania tetrandra is 0.35 g / mL based on the crude drug, i.e., 0.35 g of dry Stephania tetrandra powder is used to obtain 1 mL of Stephania tetrandra extract (solution).
[0040] The polygonatum sibiricum extract is obtained by the following method:
[0041] (1) Take an appropriate amount of dried Polygonatum sibiricum powder and place it in a supercritical fluid extraction extractor, set the temperature to 55°C, the pressure to 25 MPa, the 65% ethanol entrainer flow rate to 0.35 mL / min, and the CO2 flow rate to 2.0 mL / min. After the parameters are stable, extract and collect for 3 hours, collect the filtrate and filter it.
[0042] (2) The filtrate obtained in step (1) is concentrated under reduced pressure at 55°C to 70°C, glycerol twice the mass of the concentrate is added, the mixture is stirred and mixed evenly, and the polygonatum sibiricum extract is obtained after filtration. The concentration is 0.45 g / mL based on the crude drug, that is, 0.45 g of dry polygonatum sibiricum powder is used to obtain 1 mL of polygonatum sibiricum extract (solution).
[0043] Example 5: Acid mud film
[0044] An acid-removing mud mask product containing a skin care composition for improving skin redness and dryness was prepared, and the formula is shown in Table 2.
[0045] Table 2: Acid mud film product formula
[0046]
[0047] Preparation method of acid mud film:
[0048] S1: Preparation of water phase: Put the raw materials of phase A into the emulsification tank and stir to dissolve; disperse the raw materials of phase B separately, put them into the main pot after even dispersion, stir to dissolve; put the raw materials of phase C into the emulsification tank in turn and disperse them until there are no particles, and heat them to 80-85°C;
[0049] S2: Oil phase preparation: Put the phase D raw materials into the oil phase tank, heat to 75-80°C, and stir to melt;
[0050] S3: Emulsification: put the melted phase D raw material into the emulsification tank for emulsification and homogenization, the homogenization speed is 6000rpm, the time is 10min, and the temperature is lowered;
[0051] S4: Cool down to 45°C, add phase E (phase E is heated to 70°C in a separate clean container and stirred to dissolve) and phase F and stir to mix evenly to obtain an acid brushing mud film.
[0052] The pH value range of the product is 4.4 to 5.5. The composition can maintain the stability of the mud film product and its appearance is uniform.
[0053] The preparation method of Comparative Example 7 is the same as that of Example 5, but the skin care composition for improving skin redness and dryness is not added in Comparative Example 7.
[0054] Test Example 1: Stability Test Experiment
[0055] Examples 1 to 4 and Comparative Examples 1 to 6 were placed at room temperature, -18°C, 4°C, 45°C, and subjected to a cold and hot cycle (-18°C, 4°C, 45°C, cycled every 3 days) for a corresponding period of time for stability observation. The stability of the product was judged by whether precipitation or discoloration occurred. If no precipitation or discoloration instability occurred, the stability passed. The specific results are shown in Table 3 below.
[0056] Table 3 Stability test results
[0057]
[0058] Note: √ means the stability has passed and there is no precipitation; × means the solution has slight precipitation; ×× means the solution has severe precipitation; ○ means the solution color has changed and the color has become slightly darker; ○○ means the solution color has changed and the color has become seriously darker.
[0059] As can be seen from Table 3, when hyaluronic acid lysine copper chelate, Polygonatum sibiricum extract and Stephania tetrandra extract are all present, the solution stability is normal and can pass the stability test. Except for Comparative Example 1, when any one or two of them are present, precipitation or discoloration will occur and the stability test cannot be passed.
[0060] Test Example 2: Irritation Test
[0061] Refer to SN / T 2329-2009 "Cosmetic Eye Irritation / Chicken Embryo Chorioallantoic Membrane Test" to conduct eye irritation test, i.e. safety test, on the product.
[0062] Experimental method: Fertilized chicken embryos less than 7 days old were used and incubated in an incubator at 37.6±0.5℃ and 50%-70% humidity for 9 days.
[0063] CAM preparation: Candle the egg, mark the location of the air chamber on the eggshell surface, peel off the marked eggshell with tweezers to expose the white egg membrane, and be careful not to damage the integrity of the egg membrane. Add 0.5mL of 0.9% NaCl solution to fully moisten the egg membrane, gently absorb the surface liquid with a paper towel, and carefully remove the inner membrane with tweezers to ensure that the vascular membrane is not damaged.
[0064] Experimental method: Take 0.3 ml of liquid and apply it directly to the CAM, ensuring that 50% of the CAM surface is covered by the test substance. After 3 minutes of action, gently rinse the test substance on the CAM with physiological saline, and observe the results 30 seconds after the rinsing is completed. Set 6 chicken embryos for each test substance (Example 5 and Comparative Example 7), and set 1 chicken embryo for each negative control (physiological saline) and positive control (1% SDS).
[0065] End point score method (ES): For tests conducted using the reaction endpoint method, the endpoint score (ES) should be calculated, and the result should be rounded to two decimal places. The score for each chicken embryo = the sum of the bleeding, coagulation and vascular melting observed for each chicken embryo, ES = the mathematical sum of the scores of 6 chicken embryos. Classify the eye irritation of the test substance according to Table 4 based on the ES value.
[0066] Table 4 Criteria for determining the results of the reaction endpoint method
[0067] Stimulus score ES≤12 12<ES<16 ES≥16 Irritation classification No / mild irritation Moderate irritation Strong irritant / corrosive
[0068] Table 5 Test quality control standards and results
[0069]
[0070] This experiment met the quality control standards and the results were acceptable.
[0071] The test samples of Example 5 and Comparative Example 7 were diluted with water to 1% solution for experimental testing. The results of the irritation test are shown in Table 6. The composition of the present invention can reduce the irritation of the acid scrubbing mask to the skin and reduce the allergic irritation problem of the product.
[0072] Table 6 Statistics of irritation test results
[0073] Reaction endpoint method ES value result Example 5 0.00 Non-irritating Comparative Example 7 11.00 Mild irritation
[0074] Test Example 2: In vitro moisturizing efficacy test
[0075] AQP3 detection experiment: This test uses keratinocytes as the test model. When the plating rate reaches about 60% after cell recovery, inoculate the cells into a 24-well plate and incubate overnight in a CO2 incubator (37°C, 5% CO2). Prepare the test substance working solution according to Table 7. Each group is dosed separately, and each group has 3 replicate wells. 1mL of culture medium (KcGrowth culture medium (Guangdong Boxi Biology)) was added to each well of the blank control group, 1mL of culture medium containing CaCl2 was added to each well of the positive control group, and 1mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After the administration is completed, the 24-well plate is placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 hours.
[0076] Immunofluorescence test: Fix the cells with 4% paraformaldehyde for 24 hours, then perform immunofluorescence detection, observe under a microscope, collect and analyze the images.
[0077] HAS1 gene detection experiment: This test uses keratinocytes as the test model. When the plating rate reaches about 60% after cell recovery, the cells are inoculated into a 24-well plate and incubated overnight in a CO2 incubator (37°C, 5% CO2). Prepare the test substance working solution according to Table 7. Each group was given medication separately, and each group had 3 replicate wells. 2mL of culture solution was added to each well of the blank control group, 2mL of culture solution containing TGF-β1 was added to each well of the PC2 group, and 2mL of culture solution containing the corresponding concentration of the test sample was added to each well of the sample group. After the administration is completed, it is placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24h. After the incubation, the old solution was discarded, washed twice with PBS, 1mL of RNAiso Plus was added to each well, and the cells were lysed by blowing and collecting the samples. RNA was extracted, reverse transcribed to cDNA, and then fluorescent quantitative PCR was performed, using 2 -△△CT Method to calculate the results.
[0078] GraphPad Prism was used for graphing, and the results were expressed as Mean ± SD. The t-test was used for statistical analysis between the groups. All statistical analyses were two-tailed. P < 0.05 was considered to be significantly different, and P < 0.01 was considered to be extremely significantly different.
[0079] Table 7 Grouping settings for in vitro moisturizing efficacy test
[0080]
[0081] The test results are shown in Tables 8 and 9 respectively.
[0082] Table 8 Summary of AQP3 immunofluorescence analysis results
[0083]
[0084]
[0085] Note: The integrated optical density (IOD) reflects the content of AQP3. When the t-test method is used for statistical analysis, the significance is indicated by *, 0.01<P-value<0.05 is indicated by *, and P-value<0.01 is indicated by **.
[0086] As can be seen from Table 8, hyaluronic acid lysine copper chelate, polygonatum sibiricum extract and stephania tetrandra extract all have the effect of promoting the expression of AQP3. After the three are combined, the promotion effect on AQP3 has the effect of 1+1+1>3. Therefore, the skin care composition for improving skin redness and dryness can synergistically promote the expression of AQP3 content and has a repair effect.
[0087] Table 9 Summary of HAS1 gene analysis results
[0088] Experimental Grouping Mean SD P-value Improvement rate BC 1.00 0.06 / / PC2 1.40 0.12 0.006** 40% Example 1 1.23 0.09 0.018* 23% Example 2 1.31 0.08 0.005** 31% Example 3 1.46 0.1 0.002** 46% Example 4 1.40 0.1 0.003** 40% Comparative Example 1 1.13 0.04 0.0245* 13% Comparative Example 2 1.01 0.05 0.819 / Comparative Example 3 1.09 0.04 0.072 9% Comparative Example 4 1.14 0.03 0.014* 14% Comparative Example 5 1.10 0.06 0.091 10% Comparative Example 6 1.22 0.07 0.011* 22%
[0089] Note: Use 2 -△△CT Methods The results were calculated and the mRNA amplification fold of the BC group was normalized when the t-test method was used for statistical analysis. Compared with the BC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.
[0090] As can be seen from Table 9, the extract of Stephania tetrandra does not promote the expression of HAS1, while the hyaluronic acid lysine copper chelate and the polygonatum sibiricum extract both promote the expression of the HAS1 gene. After the three are combined, the promotion effect on the HAS1 gene has an effect of 1+1+1>3. Therefore, the skin care composition for improving skin redness and dryness can synergistically promote the expression of the HAS1 gene and has a repairing effect.
[0091] Test Example 3: In vitro inhibition of PGE2 and TNF-α activity
[0092] LPS (bacterial lipopolysaccharide) was used to induce mouse macrophage Raw264.7, and the expression of PGE2 and TNF-α was detected by ELISA method to evaluate the ability of the test substance to inhibit the expression of related cell pathway factors. See Table 10 Test scheme.
[0093] Table 10 In vitro inhibition of PGE2 and TNF-α activity experimental test scheme
[0094]
[0095]
[0096] The test results are shown in Tables 11-12.
[0097] Table 11 PGE2 content results summary
[0098] Sample name Average concentration (pg / mL) SD P-value Inhibition rate BC 370.56 21.45 / / NC 39079.32 2073.53 0.000## / PC 26853.62 1453.89 0.001** 31.28% Example 1 31689.42 1154.23 0.006** 18.91% Example 2 28613.88 1425.78 0.002** 26.78% Example 3 25233.52 1513.23 0.000** 35.43% Example 4 27253.92 1456.65 0.001** 30.26% Comparative Example 1 35214.38 856.11 0.041* 9.89% Comparative Example 2 39112.65 1402.34 0.982 / Comparative Example 3 35382.42 731.12 0.044* 9.46% Comparative Example 4 34112.34 878.91 0.019* 12.71% Comparative Example 5 33924.76 1391.35 0.023* 13.19% Comparative Example 6 30192.68 1389.24 0.004** 22.74%
[0099] Note: ## indicates that compared with blank control, p<0.01; ** indicates that compared with negative control, p<0.01; * indicates that compared with negative control, p<0.01 <p<0.05。
[0100] It can be seen from Table 11 that the extract of Stephania tetrandra cannot inhibit the expression of PGE2, hyaluronic acid lysine copper chelate and Polygonatum sibiricum extract have a certain effect of inhibiting the expression of PGE2. When all three are present, they can significantly inhibit the expression of PGE2. At the same time, Polygonatum sibiricum extract can significantly synergistically promote the inhibitory effect of hyaluronic acid lysine copper chelate and Stephania tetrandra extract on PGE2.
[0101] Table 12 TNF-α content results summary table
[0102]
[0103]
[0104] Note: ## indicates that compared with blank control, p<0.01; ** indicates that compared with negative control, p<0.01; * indicates that compared with negative control, p<0.01 <p<0.05。
[0105] It can be seen from Table 2 that hyaluronic acid lysine copper chelate cannot inhibit the expression of TNF-α, and Stephania tetrandra extract and Polygonatum sibiricum extract have a certain effect of inhibiting the expression of TNF-α. When all three are present, they can significantly inhibit the expression of TNF-α. At the same time, it can also be seen that hyaluronic acid lysine copper chelate can significantly synergistically promote the inhibitory effect of Polygonatum sibiricum extract and Stephania tetrandra extract on TNF-α.
[0106] The above results show that the product containing the skin care composition for improving skin redness and dryness can achieve the effect of soothing and moisturizing the skin, and can be used in skin care products to improve skin redness and dryness.
[0107] It should be noted that the above examples are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention is described in detail with reference to the given examples, those skilled in the art may modify or replace the technical solution of the present invention as needed without departing from the spirit and scope of the technical solution of the present invention.
Claims
1. A skin care composition for improving skin redness and dryness, characterized in that: The effective components are hyaluronic acid lysine copper chelate, Stephania tetrandra extract and polygonatum sibiricum extract, and the weight proportions of the effective components are: 0.1-1.0 parts of hyaluronic acid lysine copper chelate, 1.0-15.0 parts of Stephania tetrandra extract and 1.0-15.0 parts of polygonatum sibiricum extract.
2. The skin care composition for improving skin redness and dryness according to claim 1, characterized in that: The preparation method of the powder stephania tetrandra extract is: extracting by ultrasonic-assisted low eutectic solvent extraction, filtering the extract, concentrating the filtrate and adding butanediol to obtain the extract, wherein the concentration is 0.3-0.8 g / mL based on the crude drug.
3. The skin care composition for improving skin redness and dryness according to claim 1, characterized in that: The preparation method of the polygonatum sibiricum extract is: extracting by supercritical fluid extraction, filtering the extract, concentrating the filtrate and adding glycerol to obtain the extract, wherein the concentration is 0.4-1.0 g / mL based on the crude drug.
4. The skin care composition for improving skin redness and dryness according to any one of claims 1 to 3, characterized in that: The composition also includes solvents butylene glycol and water.
5. The skin care composition for improving skin redness and dryness according to claim 4, characterized in that: The components and weight proportions thereof are: 0.5-1.0 part of hyaluronic acid lysine copper chelate, 5.0-10.0 parts of Stephania tetrandra extract, 5.0-10.0 parts of Polygonatum sibiricum extract, 12.0-18.0 parts of butylene glycol and 100 parts of water.
6. The method for preparing the skin care composition according to claim 5, characterized in that: The polygonatum sibiricum extract, the stephania tetrandra extract and butylene glycol are mixed together, and then hyaluronic acid lysine copper chelate is added and dissolved in purified water to make up to 100 parts.
7. Use of the composition according to any one of claims 1 to 3 in the preparation of skin care cosmetics for improving skin redness and dryness.
8. The use according to claim 7, characterized in that: The composition achieves the purpose of improving skin redness and dryness by promoting the expression of moisturizing-related factors HAS1 and AQP3 and inhibiting the expression of inflammation-related factors PGE2 and TNF-α.
9. A skin care cosmetic for improving skin redness and dryness, characterized in that: A skin care composition for improving skin redness and dryness as claimed in claim 5.
10. The skin care cosmetic according to claim 9, characterized in that: Based on the total weight of the skin care cosmetic, the composition is added in an amount of 1.0-10.0%.
Citation Information
Patent Citations
Cosmetic capable of synergizing skin metabolism
CN107737091A
Facial cleanser containing rhizoma polygonati and having functions of moisturizing and repairing and preparation method thereof
CN108451862A
Plant extraction composition having efficacy of retarding skin irritation and preparation method and application of plant extraction composition
CN109846770A
Plant anti-allergy agent for skin
CN113041286A
Hyaluronic acid lysine copper chelate and application thereof
CN118307691A
